Eli Lilly (LLY) is a leading research-driven pharmaceutical company with a strong presence in the central nervous system, diabetes and obesity, and oncology markets. As equity markets adjust to recession concerns, we frequently receive inquiries from clients seeking stable market players with strong credit profiles, impressive margins of safety, and low leverage. In our view, LLY stands out as a compelling long-term investment candidate.